regenerative
TB-500 + BPC-157
A co-lyophilized research blend uniting TB-500's actin-mediated cell migration with BPC-157's growth factor signaling, engineered for protocols investigating dual-pathway tissue regeneration.
For research and laboratory use only. Not for human consumption.
Subscribe & save: $170
Quantity
Add 1 more to save 10% per unit
Technical Data
Specifications
Technical Details
Bulk Pricing
Volume Pricing Guide
Quality Assurance
Certificate of Analysis
Certificate of Analysis
COA documentation is being prepared for this product.
Contact research@roehnrx.com for batch-specific testing data.
Research Overview
About TB-500 + BPC-157
The TB-500 + BPC-157 blend brings together two of the most rigorously studied regenerative peptides into a single co-lyophilized formulation. The scientific rationale is mechanistic complementarity: BPC-157 drives repair through VEGF upregulation, nitric oxide modulation, and extracellular matrix remodeling, while TB-500 operates through actin sequestration and cytoskeletal dynamics that govern cell migration to injury sites.
Preclinical evidence across multiple tissue types — tendon, muscle, gastrointestinal mucosa, and bone — suggests that co-administration may produce outcomes exceeding those observed with either compound alone. This has made the combination a standard reference protocol in regenerative peptide research.
ROEHN formulates this blend at a 1:1 ratio by weight with each component independently verified to 99% HPLC purity prior to co-lyophilization. The single-vial format eliminates reconstitution variability and simplifies multi-peptide study designs. Individual BPC-157 and TB-500 vials are available separately for researchers requiring independent dose titration.
